Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed the 3-dose schedule >5 years previously (NC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hum Vaccin Immunother
Main Authors: Park, Juliana, Archuleta, Sophia, Oh, May-Lin Helen, Shek, Lynette Pei-Chi, Wang, Hao, Bonaparte, Matthew, Frago, Carina, Bouckenooghe, Alain, Jantet-Blaudez, Frederique, Begue, Sarah, Gimenez-Fourage, Sophie, Pagnon, Anke
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2021
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8189141/
https://ncbi.nlm.nih.gov/pubmed/33626291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2020.1861875
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados